BioMarin Pharmaceuticals

BMRN

Market cap $11.9B

Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKU SAN RAFAEL, Calif., Feb. 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ ® (pegvaliase-pqpz) to include pediatric patients 12 years of age and older with phenylketonuria (PKU).

BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit on Tuesday, March 10, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 SAN RAFAEL, Calif., Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.

BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.

Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y Led by 13% Revenue Growth for Enzyme Therapies and 31% Revenue Growth for VOXZOGO Announced Definitive Agreement to Acquire Amicus Therapeutics, including Galafold® for Fabry Disease and Pombiliti® + Opfolda® for Pompe Disease; Expected to Significantly Accelerate and Diversify Revenues BioMarin Provides 2026 Guidance Excluding any Post-Close Contribution from the Announced Acquisition of Amicus, Anticipated to Close in Q2'26 Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.

Besides Wall Street's top-and-bottom-line estimates for BioMarin (BMRN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

SAN RAFAEL, Calif., Feb. 17, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 23, 2026, at 4:30 p.m.